The purpose of the Imaging Shared Resource Core is to support innovative, multidisciplinary, translational research through the provision and support of state-of-the-art molecular, functional, and anatomical imaging. The Imaging Core works closely with UCLA Prostate SPORE investigators to implement and integrate biological imaging in their preclinical and clinical studies in order to develop key biological information to foster the optimal detection, treatment, and overall management of prostate cancer. The Imaging Core provides access to a diverse spectrum of preclinical imaging modalities, including microPET, microCT, optical (bioluminescence and fluorescence) and digital whole body autoradiography. The clinical component of the Imaging Core provides access to multiparametric MRI and MR Spectroscopy.and PET for noninvasive imaging of physiology and metabolism. In addition, targeted biopsies can be conducted using MRI/US coregistration using the Artemis system, or through CT-guided biopsy by interventional radiology. The role of the Imaging Shared Resource Core is to aid investigators in experimental design, develop standardized and quantitative approaches to image interpretation, and to solve technical hurdles. The Imaging Core also works closely with the Pathology core for targeted tissue acquisition. Centralization of these activities in a Shared Resource ensures a uniform approach and implementation across the clinical components of the SPORE projects and is critical to their success.

Public Health Relevance

The Imaging Shared Resource Core provides state-of-the-art anatomic and biological imaging expertise and services to the Prostate SPORE projects. The Imaging Core supports preclinical studies on mouse models of prostate cancer, and facilitates innovative clinical trials with prostate cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-12
Application #
8760365
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$179,156
Indirect Cost
$75,313
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:
Navarro, H├ęctor I; Goldstein, Andrew S (2018) HoxB13 mediates AR-V7 activity in prostate cancer. Proc Natl Acad Sci U S A 115:6528-6529
Mitra, Mithun; Ho, Linda D; Coller, Hilary A (2018) An In Vitro Model of Cellular Quiescence in Primary Human Dermal Fibroblasts. Methods Mol Biol 1686:27-47
Li, Jiayun; Speier, William; Ho, King Chung et al. (2018) An EM-based semi-supervised deep learning approach for semantic segmentation of histopathological images from radical prostatectomies. Comput Med Imaging Graph 69:125-133
Kang, Jung J; Reiter, Robert E; Kummer, Nicolas et al. (2018) Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. Am J Clin Oncol 41:1-5
Lee, Ha Neul; Mitra, Mithun; Bosompra, Oye et al. (2018) RECK isoforms have opposing effects on cell migration. Mol Biol Cell 29:1825-1838
Aggarwal, Rahul; Huang, Jiaoti; Alumkal, Joshi J et al. (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503

Showing the most recent 10 out of 339 publications